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Abstract 
In the fight against cancer, new and more specific targets are needed. Here, we offer an example of a potential target that has not been 
widely studied, namely the syncytin protein. Syncytin is expressed mainly in the human placenta and is implicated in placental 
syncytiotrophoblast cell fusion. Not much is known about the role of syncytin in cancer, but the existing data call for more intense 
research. Its retroviral origin and particular tissue distribution make syncytin an interesting potential target in cancer therapy.
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Translational relevance 
This paper reviews an unexplored potential new target in cancer 
therapy. We consider the origin of syncytin, its normal role in 
human placentogenesis and data regarding its relevance in 
cell–cell fusion. Given its particular distribution in normal human 
tissues and its potential roll as an immune modulator and in 
amino acid transport, tissue tolerance and protection against 
retroviral infection, syncytin could be a potential target for 
immune therapy using specific inhibitors. Current data about the 
role of syncytin in cancer are also discussed. 
 
Introduction 
Transposable elements (TEs) or mobile elements are genetic 
components that can have a significant effect on the host 
genome [1,2]. Furthermore, these elements form the majority of 
the human genome. Insertions of TEs influence the 
transcriptional regulation of some genes as well as the 
termination of transcription. Hundreds of examples have been 
identified in which individual exons possess sequences that are 
similar or identical to TE fragments [3,4]. In many of these 
cases, a single exon is involved, and its transcription yields a 
variant mRNA [5]. It has been suggested that TEs are a source 
of variation as a result of the insertion of fragments of their 
sequence into functioning genes elsewhere in the genome. 
One of the potential effects of TEs is the generation of new 
gene sequences [3,6,7] such as the envelope (env) genes of 
retroviral origin found in several mammals. In particular, the 
human genome contains full-length copies of four env open-
reading frames (ORFs) that are highly expressed in the 
placenta [8–10]. 
The best known of the human env-derived genes is syncytin-1, 
or ERVWE1, which originated from a human endogenous 
retrovirus (HERV) of the HERV-W family inserted on 
chromosome 7q21 in human-pre-hominoids 40–45 million years 
ago [11,10]. The env gene maintained an ORF coding for a 538-
amino acid polypeptide that has all the characteristic features of 
env proteins and mediates intercellular fusion in vitro [11–13]. 
Recently, a molecular evolution study of the HERV-W provirus 
in several ape species and 24 humans demonstrated the 
conservation of syncytin-1, as well as its retention of receptor-
mediated fusogenic activity [14]. However, an analysis of the 
synonymous and non-synonymous substitutions indicated a
relatively high degree of amino acid change in hominoids [15], 
which could be consistent with a low degree of selective 
pressure. HERV-W invasion of the primate genome has been 
documented as occurring before the divergence of hominoids 
and Old World monkeys [16,17] and as being inactive [18]. 
Another syncytin, syncytin-2, has also been identified; it is 
functional in all primates, including New World monkeys, but it is 
absent from prosimians, thus dating its entry into the primate 
genome to about 40 million years ago [19,20]. The syncytin-2 
gene encodes a 529-kDa polypeptide with a general 
organization similar to that of retroviral envelopes: a cleavage 
site separates the surface subunit that binds a still unidentified 
receptor on the target cell from the transmembrane subunit 
(TM), which is classically thought to be involved in the fusion 
process [21]. The TM subunit harbours an N-terminal fusion 
peptide, an ectodomain with a leucine zipper motif, a highly 
hydrophobic transmembrane anchor and a C-terminal 
intracellular domain. 
The ectodomains of retroviral envelopes are believed to play a 
pivotal role in their fusogenic function. Indeed, by analogy with 
the pre-fusion and post-fusion structures of influenza 
haemagglutinin, they include a short loop that undergoes a 
dramatic change in geometry during the fusion process [22,23] 
switching the ectodomain from an entirely a-helical to a helix-
turn-helix conformation. When the structure of the syncytin-2 
central domain is compared to that of present-day retroviruses, 
such as MoMLV and the human T-cell lymphotropic virus 
(HTLV-I), the geometries of the pivotal loops of all three 
ectodomains appear virtually identical, despite completely 
different amino acid sequences [24]. 
 
Functions of syncytin 
The HERV-derived syncytin may have played a role in the 
evolution of the human placenta due to its niche function in 
human placentogenesis, albeit in a highly specific manner, as 
the placentas of different mammalian species exhibit structural 
discrepancies [25]. 
Because of its interaction with a specific receptor known to 
function as a retrovirus receptor and an amino acid transporter, 
and its stimulation of cell–cell fusion processes, the protein was 
designated as syncytin (Figure 1). 
The syncytin receptor, or at least the first known functional 
syncytin-binding site, is the sodium-dependent neutral amino












Figure 1: Potential functions of syncytin—targeting syncitin. 
acid transporter ASCT2, which transports alanine, serine and 
cysteine. Elevated syncytin expression is followed by further cell 
differentiation and generation of the syncytium, formation of gap 
junctions and an increase in β-hCG secretion [26]. The effects 
of syncytin can be blocked in vitro by antibodies directed 
against syncytin or by the use of syncytin antisense strategies 
[11,26]. In addition to in vitro studies, it was recently 
demonstrated that the syncytin locus is strongly preserved in a 
large cohort of individuals, including long-terminal repeat (LTR) 
elements involved in the regulation of gene transcription [14]. 
Apart from these findings, orthologous syncytin loci have been 
identified in the genomes of great apes [14]; moreover, 
expression of syncytin has been described in the rhesus 
monkey endometrium, where it may play a role in 
decasualization or receptivity [27]. 
ASCT2 expression has been demonstrated predominantly at 
the basal membrane of the human syncytiotrophoblast [28–31], 
which may function as the interaction site between syncytin and 
its receptor. The observation that syncytin and ASCT2 levels 
are inversely correlated during cell syncytialization could be 
partially explained by the phenomenon that retroviruses may 
induce down-regulation of their receptors [32]. This can be 
observed after infection of cells with wild-type viruses of the 
type-D interference group, which impairs neutral amino acid 
transport [33]. 
It has been previously reported that an alteration in particular 
placental amino acid transporters is associated with intrauterine 
growth restriction (IUGR) and distinctive anthropometric 
features in the foetus, especially for system A, which transports 
neutral amino acids [34–36]. 
System A, in contrast to the ASCT2 transporter, is down-
regulated in the case of oxygen deficiency and up-regulated in 
the case of excess oxygen [28], which may contribute to foetal 
IUGR. Other transport systems, for example those for arginine, 
have been mentioned in the context of pre-eclamptic placentas 
[37]. 
Another important point concerning syncytin is its potential role 
in maternal immune tolerance to the foetus. Exogenous 
retroviral envelope proteins can inhibit the immune responses of 
leukocytes by means of a highly consistent amino acid 
sequence [38]. This sequence in the syncytin protein may 
therefore contribute to a specific immune modulating 
mechanism within the developing placenta [11]. The nature of 










additional interactions with other mechanisms such as the MHC 
class I molecules, in particular, HLA-G, which is thought to 
produce immune tolerance [39], or immunoregulatory cytokines 
such as immunosuppressive interleukin-10 [40] remains 
unclear, although syncytiotrophoblast formation stimulated by 
syncytin may subsequently ensure syncytiotrophoblast survival 
via additional interactions with immune or apoptotic 
mechanisms. Whether, or to what extent, syncytin contributes to 
maternal immune tolerance of the foetus or interacts with other 
mechanisms such as apoptotic events at the maternal–foetal 
interface is currently unclear. 
Syncytin expression has been shown to cause cellular 
resistance to infection by spleen necrosis virus [41], and it is 
likely to prevent infection by other retroviruses of the same 
family. It is thus feasible that expression of syncytin by the 
syncytiotrophoblast prevents vertical transmission of a number 
of retroviruses through the placenta. 
 
Gene promoter: description, mutations and 
repercussions. Fusion in cell lines 
The major transcription initiation site of syncytin-1 gene is 56 
base pairs (bp) downstream from a putative CCAAT box [42]. 
Deletion analysis performed on the 59-bp flanking region of the 
syncytin gene indicated that the proximal 148 bp are essential 
for minimal promoter activity and that specific regions of the 
promoter from nucleotides (nts) −1519 to −984 and nts −294 to 
−148 are required for maximal expression in normal trophoblast 
cells. DNAse-I footprint analysis of the region between nts −252 
and +110 revealed three protected regions, FP1–FP3. 
Mutagenesis of a hepatocyte-specific nuclear protein-1-binding 
site in FP1 and a TATA box in FP3 had no effect on basal 
promoter activity. On the other hand, mutation of the CCAAT 
motif and the octamer protein binding site in FP2 decreased 
promoter activity by 88% and 76%, respectively. Mutation of the 
ecdysone receptor response element in FP2, which may bind a 
nuclear hormone receptor, increased basal promoter activity. 
Gel shift and supershift assays indicated that the CCAAT-
binding factor binds to the CCAAT motif and that octamer binds 
to the octamer-binding site. Thus, it can been deduced that the 
syncytin promoter is located in the 59-bp-long terminal repeat of 
the HERV-W gene and that binding sites for GATA and Oct in 
the proximal promoter are critical for transcriptional regulation of 
syncytin in trophoblast cells [42]. 
The 146-bp stretch of the 59-bp flanking region in the human 
syncytin gene from nts 294 to 148 is essential for basal gene 
expression in human BeWo and JEG3 choriocarcinoma cell 
lines, but not in hepatoblastoma and kidney cell lines. Ligation 
of the 146-bp fragment to an SV40 (Simian Virus 40) promoter 
or a human β-globin minimal promoter markedly enhanced 
promoter activity in placental cells, but not in liver or kidney 
cells. DNase-I footprint assays indicated that nuclear extracts 
from BeWo cells, but not HepG2 cells, protected four regions 
(FP1–FP4) of the 146-bp fragment. Furthermore, site-directed 
mutagenesis of an SP1-binding site in FP3 and a GATA-binding 
site in FP4 significantly repressed promoter activity in the 
placental cells. Over-expression of SP1 (Sp1 transcription 
factor), GATA2 (GATA binding protein 2) and GATA3 induced 
syncytin promoter activity but had little or no effect on the 
activity of syncytin promoter fragments containing mutations in 
the SP1- and GATA-binding sites. In addition, GATA2 and 
GATA3 mRNA levels markedly increased during spontaneous in 
vitro differentiation of human cytotrophoblast cells after they 
fused to form a syncytium. These findings suggest that the 146-
bp region of the 59-bp flanking region (nts 2294/2148) of the 
human syncytin gene acts as a placenta-specific enhancer. 
Furthermore, binding of SP1 and GATA family members to this 
enhancer is critical for cell-specific expression of the syncytin 
gene [43]. 
 
Fusion in cancer cells 
Mortensen et al [44] found that human breast cancer cells fused 
with endothelial cells in culture. Expression of syncytin-1 protein 
has also been observed in breast cancer cell lines [45], and 
both tumour cells and endothelial cells express the syncytin-1 
receptor ASCT-2. Using syncytin-1 antisense oligonucleotides 
to down-regulate syncytin-1 expression inhibited breast cancer-
endothelial cell fusion. In addition, the syncytin-1 CHR peptide 
also inhibited cell fusion [45]. Neither the antisense nor the CHR 
peptide experiments, however, effected total inhibition of 
cancer-endothelial cell fusion. It is possible that the antisense 
oligonucleotides did not completely eliminate syncytin-1 
expression. On the other hand, syncytin-2 protein expression 
has also been documented and could contribute to cancer–host 
cell fusion. Further experiments using shRNA-directed down-
regulation of both syncytin-1 and -2 proteins, as well as 
additional putative fusogenic retroviral sequences, are 
underway to test this possibility [46]. 
These data provide strong evidence that syncytin-1 protein is 
involved in mediating cancer-endothelial cell fusion in vitro. 
The involvement of syncytin-1 in tumour cell fusion events was 
subsequently confirmed by Strick et al [47] in endometrial 
carcinomas. In their study, down-regulation of synctytin-1 










protein expression also inhibited fusion between endometrial 
tumour cells. In agreement with findings in placental cells, both 
cAMP-elevating agents and oestrogens up-regulated syncytin-1 
protein expression; however, only cAMP-elevating agents 
stimulated cell fusion [48]. This apparent discrepancy could be 
ascribed to the fact that oestrogen treatment up-regulates TGF 
beta, which interferes with syncytin-induced fusion. Indeed, 
oestrogen did stimulate cell fusion if TGF beta was neutralized 
with antibodies. Conversely, addition of TGF beta 1 or 3 
reduced the cell fusion induced by cAMP-elevating agents. This 
effect was observed in both endometrial carcinoma cells and 
trophoblast-derived cells. These results show that both cAMP 
and oestrogens may positively regulate syncytin-1 protein 
expression in tumour cells and that TGF beta family members 
may negatively regulate the fusogenic effects of syncytin-1 in 
both trophoblasts and cancer cells [48]. The role of syncytin-1 
and cell fusion in cancer requires further study. 
Published data show that the syncytin-1 protein is not the only 
fusogenic protein expressed by breast cancer cells, and the 
results presented by Strick et al [47] show that additional 
regulators, such as TGF beta isoforms, may be important 
modulators of cell fusion. 
This is not to say that cell fusion may be universally beneficial to 
all cancers. First, syncytins may have additional effects within 
the tumour environment [46,47]. Second, it seems likely that 
several factors within the cancer and its stroma (e.g., 
inactivated tumour suppressor genes, activated oncogenes and 
expression of fusogens and of CD9, CD81 and TGF beta) may 
function together to bring about a tumour profile as diverse as 
that demonstrated by the cell fusion experiments referenced 
above. Expression of CD9 has been analysed in a number of 
tumours and seems, like syncytin expression, to correlate with a 
good prognosis [48–50]. 
 
Syncytin and endometrial carcinoma 
The vast majority of endometrial carcinomas express the 
oestrogen and progesterone receptors and are thought to 
develop from endometrial hyperplasia induced by steroid 
hormone stimulation. Strick et al [47] demonstrated that 
syncytin-1 expression is regulated via an oestrogen response 
element in these steroid-driven tumours, resulting in increased 
proliferation of primary endometrial carcinoma cells and cell 
lines. It is noteworthy that activation of cAMP signalling by 
forskolin or SP-cAMP also resulted in syncytin-1 gene up-
regulation, although this intervention led to increased cell–cell 
fusion instead of proliferation. Furthermore, they showed that, 
after stimulation with steroids or cAMP activation, syncytin-1 
gene is involved in anchorage-independent colony growth and 
fusion. The switch between cell proliferation and cell-–cell fusion 
was shown to be subject to a complex regulatory mechanism 
involving both steroid hormone- and TGF-β1/TGF-β3-dependent 
effects. The authors' findings raise the possibility that syncytins 
play an important role in the progression of hormone-dependent 
cancers, such as endometrial carcinoma. In healthy individuals, 
syncytin-1 protein expression is usually restricted to the 
placenta, and it has been suggested that CpG hypomethylation 
of the 5’ LTRs of both syncytin genes is one of the underlying 
regulatory mechanisms [51]. CpG hypomethylation also 
appears to be a means of activating syncytin-1 protein 
expression in ovarian carcinoma [52]. 
Since syncytin is up=regulated in endometrial carcinoma, the 
results of Strick et al [47] suggest that syncytin-1-mediated cell 
fusion may promote rather than suppress tumour growth. They 
demonstrated that syncytin-1 expression and function are highly 
dependent on hormonal regulation: steroid hormones such as 
estradiol (E2) induce the expression of syncytin-1 protein and 
result in increased cell proliferation and anchorage-independent 
growth. On the other hand, activation of cAMP signalling 
promotes both endometrial carcinoma cell fusion and 
anchorage-independent growth. Cell fusion can be blocked by 
TGF-β1/3, which is itself subject to steroid hormone regulation. 
Thus, in the presence of steroid hormones, TGF-β provides a 
switch between syncytin-1-mediated cell fusion and cell 
proliferation. Oestrogen is a key aetiological factor in 
endometrial carcinogenesis. Regulation by TGF-β and the 
involvement of syncytin-1 add a new dimension to our 
understanding of endometrial carcinoma progression. These 
findings reveal potential new directions for therapeutic 
approaches that circumvent the need for potentially risky 
endocrinological interventions. 
The identification of syncytin as a target of TGF-β in endometrial 
carcinoma not only provides novel insight into the molecular 
mechanisms of tumour progression but may also have 
important clinical implications. A peptide capable of inhibiting 
syncytin-mediated cell–cell fusion was recently shown to reduce 
breast carcinoma cell fusion with human umbilical vein 
endothelial cells by 50% (p<0.001) [45]. While this inhibitor has 
been tested only in an experimental setting and its toxicity 
profile has not yet been evaluated, the use of this peptide or of 
related reagents may have beneficial effects in the treatment of 
endometrial and, possibly, other carcinomas. However, there is 
a need to evaluate the contribution of cell fusion to the 
malignant phenotype of endometrial carcinoma cells to rule out 
the possibility that expression of syncytin is a mere 










physiological response of the host to the tumour. Such a 
response could, for example, be aimed at neutralizing malignant 
cells via fusion with normal cells expressing tumour suppressor 
genes [53]. 
 
Syncytin and breast cancer 
Two series of human breast cancer patients were evaluated for 
tumoural expression of syncytin-1, using a polyclonal antiserum 
raised against a synthetic nanopeptide derived from the 
syncytin-1 sequence. In addition, tumours were also screened 
for expression of ASCT-2 using a peptide antiserum. Pre-
absorption of the antisera with the corresponding peptides, but 
not with irrelevant peptides, abolished staining [54]. 
The results show that 38% of all breast cancer samples 
displayed detectable staining for syncytin and that endothelial 
cells expressed ASCT-2. Moreover, significant expression of 
ASCT-2 was detected in many tumour cells. The degree of 
syncytin immunostaining was visually graded using coded 
specimens and statistical analysis showed that it correlated 
positively with the disease-free survival of patients [47]. 
Multivariate analysis included age dichotomised at 40 years, 
tumour size dichotomised at 20 mm, grade and adjuvant 
therapy, and it identified syncytin expression as an independent 
prognostic indicator of increased disease-free survival. When
used as a continuous variable, syncytin expression emerged as 
a significant prognostic indicator of disease-free survival in the 
Cox model (p = 0.02) [47]. 
 
Conclusions 
We believe that syncytins may be important fusogens for both 
trophoblast and cancer cell fusion, and that they may mediate 
additional cell fusion events, acting in concert with other 
molecules that have both enhancing and inhibitory regulatory 
effects. Both effects are relevant in mammalian 
placentogenesis. Syncytins have also been implicated in amino 
acid transport [28], immune tolerance [38] and protection 
against retroviral infections [41]. These functions of syncytin 
could all be utilized by cancers to gain a growth advantage, and, 
in our opinion, these functions should be studied in neoplasias. 
Correlations of syncytin with clinical parameters are scarce, but 
the most relevant data have been reported in breast cancer 
[53]. Besides laboratory approaches and clinical studies 
correlating syncytin-1 expression in endometrial carcinoma, 
breast carcinoma and other tumours, we believe that syncytin 
should be studied in relation to histopathological and 
clinicopathological parameters in order to assess the relevance 
of this potential novel molecular target. Its unique localization 
and distribution make syncytin attractive for the development of 
targeted therapies and immune therapies.  
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